1. Introduction {#sec1-marinedrugs-17-00710}
===============

Diabetes poses a serious threat to cardiovascular diseases, and is the eleventh common cause of disability worldwide. According to the 8th edition of the International Diabetes Federation Diabetes Atlas 2017, more than 425 million people worldwide are suffering from diabetes, and China alone accounts for one-third of that \[[@B1-marinedrugs-17-00710],[@B2-marinedrugs-17-00710]\]. Around 90% of all cases of diabetes were Type 2 diabetes mellitus \[[@B3-marinedrugs-17-00710],[@B4-marinedrugs-17-00710],[@B5-marinedrugs-17-00710]\]. *α*-Glucosidase, a crucial enzyme that breaks down complex carbohydrates for absorption, plays a key role in the treatment of diabetes. *α*-Glucosidase inhibitors such as natural products acarbose and voglibose can reduce the impact of carbohydrates on blood glucose level and prevent the digestion of carbohydrates, indicating that natural compounds play an important role in a discovery of anti-diabetic drugs \[[@B6-marinedrugs-17-00710],[@B7-marinedrugs-17-00710]\].

Mangrove-derived fungi can produce secondary metabolites with novel structures and biological activities \[[@B8-marinedrugs-17-00710]\]. In our ongoing research on mangrove-derived fungi, we have found some new bioactive metabolites (including metabolites with inhibitory activity against *α*-glucosidase) \[[@B9-marinedrugs-17-00710],[@B10-marinedrugs-17-00710],[@B11-marinedrugs-17-00710],[@B12-marinedrugs-17-00710],[@B13-marinedrugs-17-00710],[@B14-marinedrugs-17-00710]\]. A mangrove-derived fungus *Daldinia eschscholtzii* HJ004 attracted our attention due to the inhibitory activity against *α*-glucosidase of its EtOAc extract, and three polyketide derivatives with strong inhibitory activity against *α*-glucosidase have been isolated \[[@B9-marinedrugs-17-00710]\]. A further chemical investigation of the fermentation broth resulted in the identification of two new polyketides 8-*O*-methylnodulisporin F (**1**) \[[@B15-marinedrugs-17-00710]\] and nodulisporin H (**2**) \[[@B15-marinedrugs-17-00710]\], two new naphthoquinones 5-hydroxy-2-methoxy-6,7-dimethyl-1,4-naphthoquinone (**3**), and 5-hydroxy-2-methoxynaphtho\[9--*c*\]furan-1,4-dione (**4**), and a new naphthofuran 1,3,8-trimethoxynaphtho \[9--*c*\] furan (**5**), together with five known compounds, 4-*O*-methyl eleutherol (**6**) \[[@B16-marinedrugs-17-00710]\], 2-acetyl-7-methoxybenzofuran (**7**) \[[@B17-marinedrugs-17-00710]\], (-)-orthosporin (**8**) \[[@B18-marinedrugs-17-00710]\], diaporthin (**9**) \[[@B18-marinedrugs-17-00710]\], and 6-hydroxymellein (**10**) \[[@B19-marinedrugs-17-00710]\] ([Figure 1](#marinedrugs-17-00710-f001){ref-type="fig"}). The electronic circular dichroism (ECD) calculation method was used to establish the absolute configurations of the stereogenic carbons in **1** and **2**. Herein we report the isolation, structure elucidation, antibacterial activity, and inhibitory activity against *α*-glucosidase of these compounds.

2. Results and Discussion {#sec2-marinedrugs-17-00710}
=========================

Compound **1** was isolated as a white amorphous powder. Its molecular formula C~21~H~24~O~5~ (ten degrees of unsaturation) was determined by the \[+\]-HR-ESI-MS ion peak at *m*/*z* 357.1693 \[M + H\]^+^ (calcd. for 357.1697, C~21~H~25~O~5~) ([Figure S8](#app1-marinedrugs-17-00710){ref-type="app"}). The ^1^H NMR spectrum ([Figure S1](#app1-marinedrugs-17-00710){ref-type="app"}) of **1** indicated the presence of five aromatic protons at *δ*~H~ 7.14 (dd, *J* = 8.0, 7.8 Hz), 6.64 (d, *J* = 8.0 Hz), 6.55 (d, *J* = 8.0 Hz), 6.42 (d, *J* = 7.8 Hz), and 6.07 (d, *J* = 8.0 Hz), and a methoxyl signal at *δ*~H~ 3.63 (s). In addition, in the sp^3^ region of the ^1^H NMR spectrum, with the help of DEPT-135 and HMQC spectra ([Figures S1, S3 and S4](#app1-marinedrugs-17-00710){ref-type="app"}), two methine protons at *δ*~H~ 4.54 (dd, *J* = 5.2, 0.8 Hz) and 3.98 (ddq, *J* = 11.6, 6.4, 2.0 Hz), three methylenes at *δ*~H~ 3.12 (t, *J* = 7.2 Hz), (2.07 (dt, *J* = 14.0, 2.0 Hz), 1.89 (ddd, *J* = 14.0, 11.6, 5.2 Hz)), and 1.75 (m), and two methyls at *δ*~H~ 1.30 (d, *J* = 6.4 Hz) and 1.01 (t, *J* = 7.4 Hz) were observed, respectively. The ^13^C NMR spectrum showed 21 carbon signals, which, in combination with DEPT-135 and HSQC spectra ([Figures S2--S4](#app1-marinedrugs-17-00710){ref-type="app"}), can be categorized as three methyls (*δ*~C~ 55.8, 21.5, and 14.1), three methylene sp^3^ (*δ*~C~ 46.8, 34.5, and 17.9), two methine sp^3^ (δ~C~ 67.9 and 29.5), five methine sp^2^ (δ~C~ 135.3, 128.1, 109.7, 105.4, and 102.2), seven non-protonated sp^2^ (*δ*~C~ 161.0, 158.1, 156.8, 156.2, 126.0, 111.7, and 109.5) and one carbonyl (*δ*~C~ 208.1) carbons. The above NMR data suggested that the structure of **1** was very similar to that of nodulisporin F \[[@B20-marinedrugs-17-00710]\] except for the presence of the methoxyl group (*δ*~H~ 3.63/*δ*~C~ 55.7). That the methoxyl group was located at C-8′ was confirmed by the HMBC correlation from 8′-OMe (*δ*~H~ 3.63) to C-8′ (*δ*~C~ 158.1) and the NOESY correlation from H-7′ (*δ*~H~ 6.42) to 8′-OMe ([Figures S6 and S7](#app1-marinedrugs-17-00710){ref-type="app"}). The 2D NMR data allowed to elucidate the complete planar structure of **1** ([Figure 2](#marinedrugs-17-00710-f002){ref-type="fig"} and [Figures S4--S6](#app1-marinedrugs-17-00710){ref-type="app"}).

The relative configurations of the C-1′ and C-3′ estereogenic centers were deduced by the coupling constants (*J*~1′,2′a~ = 5.2 Hz and *J*~3′,2′a~ = 11.6 Hz) in the ^1^H NMR spectrum. The small coupling constant of 5.2 Hz between H-1′ and H-2′a established that H-1′ was in equatorial orientation. By contrast, the coupling constant for *J*~3′,2′a~ = 11.6 Hz indicated the axial orientation of H-3′, and the equatorial position of the Me-3′. These results implied that H-1′ and H-3′ were on the opposite sides. Besides, the NOESY spectrum of **1** showed correlations between H-1′ and H-2′a, as well as between H-3′ and H-2′b ([Figure S7](#app1-marinedrugs-17-00710){ref-type="app"}). Furthermore, the chemical shifts and coupling constants of H-1′/ H-2′/ H-3′/ H-4′ were close to those of nodulisporin F \[[@B20-marinedrugs-17-00710]\], which suggested a similar configuration. Thus, the relative configurations of **1** were confirmed as 1′*R*\*,3′*S*\*, and **1** was named 8-*O*-methylnodulisporin F.

Compound **2** was also isolated as a white amorphous powder with the same molecular formula as **1**, based on the \[+\]-HR-ESI-MS ion peak at *m*/*z* 357.1693 \[M + H\]^+^ (calcd. for 357.1697, C~21~H~25~O~5~) ([Figure S16](#app1-marinedrugs-17-00710){ref-type="app"}). Its ^1^H- and ^13^C-NMR data closely resembled those of **1**, except for the coupling constants between H-1′ and H-2′ (*J*~1′,2′~ = 10.4, 8.0 Hz) in the ^1^H NMR spectrum ([Table 1](#marinedrugs-17-00710-t001){ref-type="table"} and [Figure S9](#app1-marinedrugs-17-00710){ref-type="app"}). The large coupling constants of *J*~1′,2′a~= 10.4 Hz and *J*~3′,2′a~ = 11.2 Hz confirmed that H-1′ and H-3′ were both in the axial orientation. Additionally, the NOESY spectrum of **2** showed correlations between H-1′ and H-2′b, as well as between H-3′ and H-2′b ([Figure S15](#app1-marinedrugs-17-00710){ref-type="app"}). These results indicated the relative configurations of **2** as 1′*R*\*,3′*R*\*, and **2** was named as nodulisporin H. Therefore, **1** and **2** are C-3′ epimers.

The absolute configurations of C-1′ and C-3′ in **1** and **2** were determined by comparison of experimental and calculated ECD spectra. The calculated ECD curve of 1′*R*,3′*S* matched well the experimental ECD curve of **1**, while the calculated ECD spectrum of the 1′*R*,3′*R* matched well the experimental ECD spectrum of **2** ([Figure 3](#marinedrugs-17-00710-f003){ref-type="fig"}).

Compound **3** was obtained as a yellow powder. The \[+\]-HR-ESI-MS ion peak at *m*/*z* 233.0809 \[M + H\]^+^ (calcd. for 233.0808, C~13~H~13~O~4~) indicated that the molecular formula of **3** was C~13~H~12~O~4~ (eight degrees of unsaturation) ([Figure S21](#app1-marinedrugs-17-00710){ref-type="app"}). Its ^1^H NMR data ([Table 2](#marinedrugs-17-00710-t002){ref-type="table"}) displayed one chelated hydroxyl proton at *δ*~H~ 12.61 (s, OH-5), one aromatic proton at *δ*~H~ 7.50 (s, H-8), one olefinic proton at *δ*~H~ 6.05 (s, H-3), one methoxyl at *δ*~H~ 3.90 (s, OMe-2), and two methyls at *δ*~H~ 2.36 (s, Me-10) and 2.25 (s, Me-9). The ^13^C NMR spectrum, in combination with the HMQC spectrum ([Figures S18 and S19](#app1-marinedrugs-17-00710){ref-type="app"}), displayed 13 carbon signals, which consisted of two carbonyl carbons at *δ*~C~ 190.9 and 179.8, six non-protonated sp^2^ carbons at *δ*~C~ 161.2, 159.7, 159.7, 145.1, 134.2, and 111.7, two protonated sp^2^ carbons at *δ*~C~ 121.4 and 109.5, one methoxyl carbon at *δ*~C~ 56.7, and two methyl carbons at *δ*~C~ 20.8 and 11.9. The ^1^H and ^13^C NMR data of **3** ([Table 2](#marinedrugs-17-00710-t002){ref-type="table"}) were very similar to those of 2-methoxy-7-methyljuglone \[[@B21-marinedrugs-17-00710]\]. The only difference was the presence of the methyl group on C-6 in **3**, which was supported by the HMBC correlations from Me-9 to C-5 and C-7. The HMQC and HMBC spectra ([Figures S19 and S20](#app1-marinedrugs-17-00710){ref-type="app"}) confirmed the structure of **3** ([Figure 2](#marinedrugs-17-00710-f002){ref-type="fig"}) as 5-hydroxy-2-methoxy-6,7-dimethyl-1,4-naphthoquinone.

Compound **4** was obtained as a brown powder, with the molecular formula C~13~H~10~O~5~ (nine degrees of unsaturation) based on the \[+\]-HR-ESI-MS at 247.0605 \[M + H\]^+^ (calcd. for 247.0601, C~13~H~11~O~5~) ([Figure S26](#app1-marinedrugs-17-00710){ref-type="app"}). The ^1^H and ^13^C NMR data of **4** ([Table 2](#marinedrugs-17-00710-t002){ref-type="table"}) were similar to those of **3**. The obvious difference was that Me-9 (*δ*~H~ 2.25/*δ*~C~ 11.9) and Me-10 (*δ*~H~ 2.36/*δ*~C~ 20.8) in **3** were replaced by two oxymethylene carbons at *δ*~C~ 72.1 (C-9; *δ*~H~ 5.20) and 74.3 (C-10; *δ*~H~ 5.16) in **4**. Combination of the ^1^H and ^13^C NMR data with the molecular formula of **4** indicated the presence of a tetrahydrofuran ring. Therefore, the structure of **4** was established as 5-hydroxy-2-methoxynaphtho \[9--*c*\] furan-1,4-dione.

Compound **5** was isolated as a yellow powder, with the molecular formula of C~15~H~16~O~4~ (eight degrees of unsaturation) based on \[+\]-HR-ESI-MS at *m*/*z* 261.1118 \[M + H\]^+^ (calcd. for 261.1121, C~15~H~17~O~4~) ([Figure S31](#app1-marinedrugs-17-00710){ref-type="app"}). The ^1^H and ^13^C NMR data ([Table 2](#marinedrugs-17-00710-t002){ref-type="table"}), assigned with the help of the HMQC spectrum ([Figure S29](#app1-marinedrugs-17-00710){ref-type="app"}), exhibited the presence of three aromatic protons at *δ*~H~ 7.30 (s, H-5), 6.71 (d, *J* = 2.2 Hz, H-2), and 6.51 (d, *J* = 2.2 Hz, H-4), three methoxyl signals at *δ*~H~ 3.97 (s, OMe-1), 3.89 (s, OMe-3), and 3.84 (s, OMe-8), and two oxymethylene signals at *δ*~H~ 5.26 (s, H-10) and 5.16 (s, H-9). The ^13^C NMR spectrum ([Table 2](#marinedrugs-17-00710-t002){ref-type="table"}), in combination with the HMQC spectrum ([Figures S28 and S29](#app1-marinedrugs-17-00710){ref-type="app"}), displayed 15 carbon signals, consisting of seven non-protonated sp^2^ (*δ*~C~ 158.1, 157.5, 150.6, 140.5, 139.0, 127.7, and 115.4), three protonated sp^2^ (*δ*~C~ 114.5, 99.0, and 98.8), two oxymethylene sp^3^ (*δ*~C~ 73.3 and 71.7) and three methoxyl (*δ*~C~ 61.6, 56.2, and 55.4) carbons. The HMBC correlations from H-9 (*δ*~H~ 5.16) to C-5 (*δ*~C~ 114.5), C-7 (*δ*~C~ 140.5) and C-10 (*δ*~C~ 71.7) as well as from H-10 (*δ*~H~ 5.26) to C-6 (*δ*~C~ 127.7) and C-8 (*δ*~C~ 150.6) suggested the presence of a naphthofuran skeleton. Furthermore, the HMBC correlations from OMe-1(*δ*~H~ 3.97) to C-1 (*δ*~C~ 157.5), OMe-3 (*δ*~H~ 3.89) to C-3 (*δ*~C~ 158.1), and OMe-8 (*δ*~H~ 3.84) to C-8 (*δ*~C~ 150.6) established the positions of the three methoxyls at C-1, C-3 and C-8, respectively. Thus, the structure of **5** was elucidated as 1,3,8-trimethoxynaphtho \[9--*c*\] furan.

Compounds **4** and **7** displayed potent inhibitory activity on *α*-glucosidase with the IC~50~ values of 5.7 and 1.1 μg/mL, respectively. The rest of the isolated compounds exhibited no inhibitory activity against *α*-glucosidase. Acarbose was used as a positive control (IC~50~ = 2.0 μg/mL).

Compounds **1** and **2** showed moderate antibacterial activity against *Staphylococcus aureus*, Methicillin-resistant *S. aureus* MRSA and *Bacillus cereus*, with minimum inhibitory concentration (MIC) values ranging from 6.25 to 12.5 μg/mL ([Table 3](#marinedrugs-17-00710-t003){ref-type="table"}). Compound **3** exhibited antibacterial activity against *B. cereus* with the MIC value of 12.5 μg/mL ([Table 3](#marinedrugs-17-00710-t003){ref-type="table"}). The other compounds showed no antibacterial activity against six pathogenic bacteria.

3. Materials and Methods {#sec3-marinedrugs-17-00710}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-17-00710}
------------------------------------

Both 1D and 2D NMR spectra were measured on a Bruker AV-400 (Bruker Corporation, Fällanden, Switzerland) instrument by using CDCl~3~ as a solvent with TMS as the internal standard. The other experimental procedures were performed as previously described in the literature \[[@B9-marinedrugs-17-00710]\].

3.2. Fungal Material {#sec3dot2-marinedrugs-17-00710}
--------------------

The strain HJ004 was isolated from the stem of mangrove *Brguiera sexangula* var. *rhynchopetala*, collected in the South China Sea, and was identified as *Daldinia eschscholtzii* with the GeneBank (NCBI) accession number MH059553 \[[@B9-marinedrugs-17-00710]\]. This strain was deposited at the Key Laboratory of Tropical Medicinal Resource Chemistry of Ministry of Education, Hainan Normal University, Haikou, China.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-17-00710}
-----------------------------

The fermentation was carried out statically in 45 L of potato glucose liquid medium at 25 °C for one month. The fermented broths were filtered through cheesecloth, and the filtrate was extracted with EtOAc (3 × 45 L, 48 h each). The EtOAc extracts were combined and concentrated under reduced pressure to yield a residue of 64.0 g, which was fractionated by vacuum liquid chromatography (VLC) with a petroleum ether-EtOAc-MeOH gradient, to yield five fractions (Frs. 1−5). Fr. 2 was subjected to a Sephadex LH-20 (300 g) column chromatography (CC) eluting with petroleum ether-CHCl~3~-MeOH (1:1:1, *v*/*v*/*v*), and then further purified by using semi-preparative HPLC (85% MeOH-H~2~O) to give **1** (2.0 mg) and **2** (2.2 mg). Fr. 3 was applied on the VLC to obtain three subfractions: Frs. 3.1−3.3. Compound **3** was obtained from Fr. 3.1 using Sephadex LH-20 CC (petroleum ether/CHCl~3~/MeOH, 2:1:1, *v*/*v*/*v*). Fr. 4 was subjected to a silica gel (200 g) CC and eluted with a step gradient of petroleum ether/EtOAc to obtain four subfractions: Frs. 4.1−4.4. Fr. 4.1 was subjected to a Sephadex LH-20 column (300 g) eluted with CHCl~3~: MeOH (1:1) and then semi-preparative HPLC (65% MeOH/H~2~O) to yield **5** (3.0 mg) and **6** (5.5 mg). Fr. 4.2.4 was isolated from Fr. 4.2 by reversed-phase silica gel CC, and then purified by HPLC (75% MeOH/H~2~O) to give **4** (4.6 mg) and **7** (3.7 mg). Fr. 4.3 was further separated by reversed-phase silica gel (50 g) CC and eluted with MeOH/H~2~O gradients from 50:50 to 100:0 (*v*/*v*) into three subfractions Frs. 4.3.1−4.3.3. Fr. 4.3.2 was purified by HPLC (55% MeOH/H~2~O) to yeild **8** (3.5 mg), **9** (4.3 mg), and **10** (4.5 mg).

*8-O-methylnodulisporin F* (**1**): white amorphous powder; \[*α*\]^25^~D~ = −17.8° (*c* 0.18, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 210 (2.31), 228 (2.42); IR (KBr) *ν*~max~ 3261, 1636, 1270 cm^−1^; CD (*c* 0.06, MeOH) *λ*~max~ (Δ*ε*) 212 (+0.6), 239 (−1.2) nm. ^1^H and ^13^C NMR data see [Table 1](#marinedrugs-17-00710-t001){ref-type="table"}; \[+\]-HR-ESI-MS *m*/*z*: 357.1693 \[M + H\]^+^ (calcd. for C~21~H~25~O~5~ 357.1697).

*Nodulisporin H* (**2**): white amorphous powder; \[*α*\]^25^~D~ = +10.6° (*c* 0.26, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 217 (3.21), 260 (2.12); IR (KBr) *ν*~max~ 3259, 1620, 1256 cm^−1^; CD (*c* 0.1, MeOH) *λ*~max~ (Δ*ε*) 216 (−3.0), 256 (−0.7) nm. ^1^H and ^13^C NMR data see [Table 1](#marinedrugs-17-00710-t001){ref-type="table"}; \[+\]-HR-ESI-MS *m*/*z*: 357.1693 \[M + H\]^+^ (calcd. for C~21~H~25~O~5~ 357.1697).

*5-Hydroxy-2-methoxy-6,7-dimethyl-1,4-naphthoquinone* (**3**): yellow powder; UV (MeOH) *λ*~max~ 282 (4.20), 249 (3.40), 217 (3.26) nm; IR (KBr) *ν*~max~ 3240, 1865, 1680 cm^−1^; ^1^H and ^13^C NMR data see [Table 2](#marinedrugs-17-00710-t002){ref-type="table"}; \[+\]-HR-ESI-MS *m*/*z*: 233.0809 \[M + H\]^+^ (C~13~H~13~O~4~, calcd. for 233.0808).

*5-Hydroxy-2-methoxynaphtho \[9--c\] furan-1,4-dione* (**4**): brown powder; UV (MeOH) *λ*~max~ 301 (3.80), 250 (3.12), 217 (2.90) nm; IR (KBr) *ν*~max~ 3246, 1864, 1680 cm^−1^; ^1^H and ^13^C NMR data see [Table 2](#marinedrugs-17-00710-t002){ref-type="table"}; \[+\]-HR-ESI-MS *m*/*z*: 247.0605 \[M + H\]^+^ (C~13~H~11~O~5~, calcd. for 247.0601).

*1*,*3*,*8-Trimethoxynaphtho \[9--c\] furan* (**5**): yellow powder; UV (MeOH) *λ*~max~ 278 (3.60) nm; IR (KBr) *ν*~max~ 3500, 1632 cm^−1^; ^1^H and ^13^C NMR data see [Table 2](#marinedrugs-17-00710-t002){ref-type="table"}; \[+\]-HR-ESI-MS *m*/*z*: 261.1118 \[M + H\]^+^ (C~15~H~17~O~4~, calcd. for 261.1121).

3.4. Biological Assay {#sec3dot4-marinedrugs-17-00710}
---------------------

The *α*-glucosidase inhibitory activity of **1**--**10** was determined using the procedure reported by Sawada et al. \[[@B22-marinedrugs-17-00710]\], with modifications for carrying out in 96-well plates, and acarbose was used as a positive control.

Compounds **1**--**10** were assayed against four terrestrial pathogenic bacteria *Staphylococcus aureus* (ATCC 25923), methicillin-resistant *S. aureus* MRSA (ATCC 33591), *Escherichia coli* (ATCC 25922), and *Bacillus cereus* (ATCC 11778), and two marine pathogenic bacteria *Vibrio parahaemolyticus* (ATCC 17802) and *V. alginolyticus* (ATCC 17749), and the tests were performed as previously described \[[@B23-marinedrugs-17-00710]\]. Ciprofloxacin was used as the positive control.

4. Conclusions {#sec4-marinedrugs-17-00710}
==============

From the mangrove-derived fungus *Daldinia eschscholtzii* HJ004, two new polyketides 8-*O*-methylnodulisporin F (**1**) and nodulisporin H (**2**), two new naphthoquinones 5-hydroxy-2-methoxy-6,7-dimethyl-1,4-naphthoquinone (**3**), 5-hydroxy-2-methoxy-naphtho \[9--*c*\] furan-1,4-dione (**4**), and a new naphthofuran 1,3,8-trimethoxynaphtho \[9--*c*\] furan (**5**), and five known compounds (**6**--**10**) were obtained. Compounds **4** and **7** displayed potent inhibitory activity against *α*-glucosidase with the IC~50~ values of 5.7 and 1.1 μg/mL, respectively. Compounds **1** and **2** showed moderate antibacterial activity against *S. aureus*, Methicillin-resistant *S. aureus* MRSA and *B. cereus* with MIC values ranging from 6.25 to 12.5 μg/mL. Compound **3** exhibited antibacterial activity against *B. cereus* with the MIC value of 12.5 μg/mL.
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###### 

^1^H and ^13^C NMR spectroscopic data (400 and 100 MHz) for **1** and **2** in CDCl~3~.

  Position   1             2                                                               
  ---------- ------------- ------------------------------------------------- ------------- --------------------------------------------------------
  1          126.0, C                                                        125.7, C      
  2          135.3, CH     6.64, d (8.0)                                     134.0, CH     6.90, d (8.4)
  3          105.4, CH     6.07, d (8.0)                                     107.6, CH     6.22, d (8.4)
  4          156.2, C                                                        158.8, C      
  5          208.1, C                                                        208.1, C      
  6          46.8, CH~2~   3.12, t (7.2)                                     46.9, CH~2~   3.10, dd (7.8, 6.6)
  7          17.9, CH~2~   1.75, m                                           18.0, CH~2~   1.73, m
  8          14.1, CH~3~   1.01, t (7.4)                                     14.0, CH~3~   0.99, t (7.4)
  9          161.0, C                                                        158.3, C      
  10         111.7, C                                                        110.2, C      
  1′         29.5, CH      4.54, dd (5.2, 0.8)                               32.0, CH~2~   4.44, dd (10.4, 8.0)
  2′         34.5, CH~2~   1.89, ddd (14.0, 11.6, 5.2)2.07, dt (14.0, 2.0)   39.1, CH~2~   1.77, ddd (14.0, 11.2, 10.4)2.39, ddd (14.0, 8.0, 1.6)
  3′         67.9, CH      3.98, ddq (11.6, 6.4, 2.0)                        72.6, CH      4.09, ddq (11.2, 6.4, 1.6)
  5′         109.7, CH     6.55, brd (8.0)                                   110.5, CH     6.58, br d (8.0)
  6′         128.1, CH     7.14, dd (8.0, 7.8)                               127.8, CH     7.11, dd (8.0, 7.8)
  7′         102.2, CH     6.42, d (7.8)                                     103.8, CH     6.42, br d (7.8)
  8′         158.1, C                                                        158.6, C      
  9′         156.8, C                                                        158.0, C      
  10′        109.5, C                                                        114.0, C      
  3′-Me      21.5, CH~3~   1.30, d (6.4)                                     21.3, CH~3~   1.38, d (6.4)
  8′-OMe     55.8, CH~3~   3.63, s                                           55.7, CH~3~   3.48, s
  9-OH                     13.1, s                                                         
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###### 

^1^H and ^13^C NMR spectroscopic data (400 and 100 MHz) for **3**--**5** in CDCl~3~.

  Position   3             4          5                                      
  ---------- ------------- ---------- ------------- ---------- ------------- ---------------
  1          179.8, C                 179.4, C                 157.5, C      
  2          161.2, C                 161.3, C                 99.0, CH      6.71, d (2.2)
  3          109.5, CH     6.05, s    109.5, CH     6.08, s    158.1, C      
  4          190.9, C                 191.0, C                 98.8, CH      6.51, d (2.2)
  4a         111.7, C                 113.9, C                 139.0, C      
  5          159.7, C                 156.0, C                 114.5, CH     7.30, s
  6          134.2, C                 134.7, C                 127.7, C      
  7          145.1, C                 147.9, C                 140.5, C      
  8          121.4, CH     7.50, s    112.6, CH     7.56, s    150.6, C      
  8a         159.7, C                 131.8, C                 115.4, C      
  9          11.9, CH~3~   2.25, s    72.1, CH~2~   5.20, s    73.3, CH~2~   5.16, s
  10         20.8, CH~3~   2.36, s    74.3, CH~2~   5.16, s    71.7, CH~2~   5.26, s
  1-OMe                                                        56.2, CH~3~   3.97, s
  2-OMe      56.7, CH~3~   3.90, s    56.9, CH~3~   3.93, s                  
  3-OMe                                                        55.4, CH~3~   3.89, s
  8-OMe                                                        61.6, CH~3~   3.84, s
  5-OH                     12.61, s                 12.34, s                 
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Antibacterial activity for **1**--**3**.

  Compound              MIC (μg/mL)          
  --------------------- ------------- ------ ------
  **1**                 6.25          12.5   6.25
  **2**                 12.5          12.5   6.25
  **3**                 \>25          \>25   12.5
  Ciprofloxacin *^a^*   0.31          1.25   1.25

Ciprofloxacin *^a^* was used as a positive control.
